Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain

J del Amo, C González, J Losana, P Clavo, L Muñoz, J Ballesteros, A García-Saiz, M J Belza, M Ortiz, B Menéndez, J del Romero, F Bolumar, J del Amo, C González, J Losana, P Clavo, L Muñoz, J Ballesteros, A García-Saiz, M J Belza, M Ortiz, B Menéndez, J del Romero, F Bolumar

Abstract

Objectives: To estimate the prevalence and risk factors of high risk human papillomavirus (HPV) infection in migrant female sex workers (FSW) according to age and geographical origin.

Methods: Cross sectional study of migrant FSW attending a sexually transmitted infection (STI) clinic in Madrid during 2002. Information on sociodemographic characteristics, reproductive and sexual health, smoking, time in commercial sex work, history of STIs, HIV, hepatitis B, hepatitis C, syphilis, and genitourinary infections was collected. High risk HPV Infection was determined through the Digene HPV Test, Hybrid Capture II. Data were analysed through multiple logistic regression.

Results: 734 women were studied. Overall HPV prevalence was 39%; 61% in eastern Europeans, 42% in Ecuadorians, 39% in Colombians, 29% in sub-Saharan Africans, and 24% in Caribbeans (p = 0.057). HPV prevalence showed a decreasing trend by age; 49% under 20 years, 35% in 21-25 years,14% over 36 years% (p<0.005). In multivariate analyses, area of origin (p = 0.07), hormonal contraception in women not using condoms (OR 19.45 95% CI: 2.45 to 154.27), smoking, age, and an interaction between these last two variables (p = 0.039) had statistically significant associations with HPV prevalence. STI prevalence was 11% and was not related to age or geographical origin.

Conclusions: High risk HPV prevalence in migrant FSW is elevated and related to age, area of origin, and use of oral contraceptives in women not using condoms. These data support the role of acquired immunity in the epidemiology of HPV infection and identifies migrant FSW as a priority group for sexual health promotion.

References

    1. Med Clin (Barc). 2000 Jun 17;115(3):81-4
    1. J Natl Cancer Inst. 1999 Mar 17;91(6):506-11
    1. J Obstet Gynaecol Res. 2000 Aug;26(4):253-7
    1. Sex Transm Dis. 2001 Mar;28(3):125-30
    1. Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7
    1. J Environ Pathol Toxicol Oncol. 2001;20(2):113-7
    1. JAMA. 2001 Jun 20;285(23):2995-3002
    1. Lancet. 2001 Jun 9;357(9271):1831-6
    1. Eur J Gynaecol Oncol. 2001;22(3):204-8
    1. JAMA. 2001 Dec 26;286(24):3106-14
    1. J Clin Microbiol. 2001 Dec;39(12):4344-8
    1. Lancet Oncol. 2002 Jan;3(1):11-6
    1. Lancet. 2002 Mar 30;359(9312):1085-92
    1. Sex Transm Infect. 2002 Aug;78(4):250-4
    1. Int J Cancer. 2003 Mar 1;103(6):705-8
    1. Am J Epidemiol. 2003 Feb 1;157(3):218-26
    1. N Engl J Med. 2003 Feb 6;348(6):518-27
    1. Lancet. 2003 Apr 5;361(9364):1159-67
    1. Br J Cancer. 2003 Jun 2;88(11):1713-20
    1. Am J Epidemiol. 2003 Sep 1;158(5):486-94
    1. Lancet. 1987 Sep 26;2(8561):703-6
    1. J Infect Dis. 1994 Feb;169(2):235-40
    1. Sex Transm Dis. 1995 Mar-Apr;22(2):119-27
    1. Sex Transm Dis. 1996 Jul-Aug;23(4):333-41
    1. N Engl J Med. 1998 Feb 12;338(7):423-8
    1. Epidemiol Infect. 1998 Aug;121(1):173-7
    1. Sex Transm Dis. 2000 Sep;27(8):438-45

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner